HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-28. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
Advancement of the first-in-class KRAS-EGFR conjugate into human trials de-risks HUTCHMED and GSK's collaborative oncology pipeline, unlocking future milestone payments and commercial licensing value.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factHUTCHMED initiated a Phase Ia global clinical trial evaluating HMPL-A830 in patients with solid tumors. |
| What else was confirmed? | Reported factThe first patient was dosed on September 24, 2026. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for HCM yet — this is the next research task. |
| What would change the assessment? | UnknownHMPL-A830 Phase Ia Safety Updates — Monitor clinical trial registry updates and medical conference abstract submissions for cohort enrollment progress. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · HUTCHMED initiated a Phase Ia global clinical trial evaluating HMPL-A830 in patients with solid tumors.
- · The first patient was dosed on September 24, 2026.
- · HMPL-A830 is an antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody.
- · HUTCHMED operates under an exclusive development and commercialization partnership with GSK.
Public research record
Research framework · page evidenceCompleted event assessment
clinical pipeline milestone progression in exclusive partnered oncology asset
| Type | Claim | Scope |
|---|---|---|
| Assumption | HUTCHMED initiated a Phase Ia global clinical trial evaluating HMPL-A830 in patients with solid tumors. | 2026-09-28 |
| Interpretation | clinical pipeline milestone progression in exclusive partnered oncology asset | HCM |
Countercase, invalidators, and sources
Phase Ia dose-escalation demonstrates acceptable safety profiles and initial tumor response signals, progressing to combination cohorts.
- · HMPL-A830 Phase Ia Safety Updates — Monitor clinical trial registry updates and medical conference abstract submissions for cohort enrollment progress.
- HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors · 2026-09-28
What remains unresolved
- Base path
- Trial enrollment proceeds as planned across international sites, with interim safety data expected in 2027.
- Adverse path
- Dose-limiting toxicities emerge in early cohorts, requiring dosage adjustments or protocol modifications.
- Supportive path
- Phase Ia dose-escalation demonstrates acceptable safety profiles and initial tumor response signals, progressing to combination cohorts.
- · HMPL-A830 Phase Ia Safety Updates — Monitor clinical trial registry updates and medical conference abstract submissions for cohort enrollment progress.next month
Evidence
- HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors2026-09-28
“HUTCHMED has initiated a Phase Ia global clinical trial of HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody for treating solid tumors. The first patient was dosed on September 24, 2026. HUTCHMED entered an exclusive development and commercialization agreement with GSK.”
Supports: HUTCHMED initiated Phase Ia trial of HMPL-A830 with first patient dosed on Sept 24, 2026 under GSK partnership.